Shares of Cellectis S.A. (NASDAQ:CLLS) fell 5.7% during mid-day trading on Tuesday . The company traded as low as $18.80 and last traded at $21.94. 706,248 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 465,118 shares. The stock had previously closed at $23.26.
A number of brokerages recently issued reports on CLLS. Zacks Investment Research upgraded Cellectis from a “sell” rating to a “hold” rating in a research note on Monday, February 8th. William Blair restated a “buy” rating on shares of Cellectis in a research note on Wednesday, November 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $23.40.
The company has a current ratio of 6.11, a quick ratio of 6.00 and a debt-to-equity ratio of 0.10. The company has a 50-day simple moving average of $28.25 and a 200 day simple moving average of $22.72. The firm has a market cap of $932.14 million, a PE ratio of -11.16 and a beta of 2.59.
About Cellectis (NASDAQ:CLLS)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia.
See Also: Percentage Gainers
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.